154 related articles for article (PubMed ID: 38454120)
1. The dual HCK/BTK inhibitor KIN-8194 impairs growth and integrin-mediated adhesion of BTKi-resistant mantle cell lymphoma.
Lantermans HC; Ma F; Kuil A; van Kesteren S; Yasinoglu S; Yang G; Buhrlage SJ; Wang J; Gray NS; Kersten MJ; Treon SP; Pals ST; Spaargaren M
Leukemia; 2024 Mar; ():. PubMed ID: 38454120
[TBL] [Abstract][Full Text] [Related]
2. The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance.
Yang G; Wang J; Tan L; Munshi M; Liu X; Kofides A; Chen JG; Tsakmaklis N; Demos MG; Guerrera ML; Xu L; Hunter ZR; Che J; Patterson CJ; Meid K; Castillo JJ; Munshi NC; Anderson KC; Cameron M; Buhrlage SJ; Gray NS; Treon SP
Blood; 2021 Nov; 138(20):1966-1979. PubMed ID: 34132782
[TBL] [Abstract][Full Text] [Related]
3. BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naive mantle cell lymphoma.
Eyre TA; Shah NN; Dreyling M; Jurczak W; Wang Y; Cheah CY; Song Y; Gandhi M; Chay C; Sharman J; Andorsky DJ; Messersmith HM; Ruppert AS; Muthig VA; Ito R; Wang ML
Future Oncol; 2022 Nov; 18(36):3961-3969. PubMed ID: 36377973
[TBL] [Abstract][Full Text] [Related]
4. Distinct BTK inhibitors differentially induce apoptosis but similarly suppress chemotaxis and lipid accumulation in mantle cell lymphoma.
Liu Z; Liu J; Zhang T; Li L; Zhang S; Jia H; Xia Y; Shi M; Zhang J; Yue S; Chen X; Yu J
BMC Cancer; 2021 Jun; 21(1):732. PubMed ID: 34174847
[TBL] [Abstract][Full Text] [Related]
5. Revealing the Role of the Arg and Lys in Shifting Paradigm from BTK Selective inhibition to the BTK/HCK Dual inhibition- Delving into the Inhibitory Activity of KIN-8194 Against BTK, and HCK in the Treatment of Mutated 〖BTK〗^Cys481 Waldenström Macroglobulinemia: A computational Approach.
Elamin G; Aljoundi A; Alahmdi M; Abo-Dya NE; Soliman M
Anticancer Agents Med Chem; 2023 Feb; ():. PubMed ID: 36752293
[TBL] [Abstract][Full Text] [Related]
6. Identification of the SRC-family tyrosine kinase HCK as a therapeutic target in mantle cell lymphoma.
Lantermans HC; Minderman M; Kuil A; Kersten MJ; Pals ST; Spaargaren M
Leukemia; 2021 Mar; 35(3):881-886. PubMed ID: 32591642
[TBL] [Abstract][Full Text] [Related]
7. Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma.
Jiang VC; Liu Y; Lian J; Huang S; Jordan A; Cai Q; Lin R; Yan F; McIntosh J; Li Y; Che Y; Chen Z; Vargas J; Badillo M; Bigcal JN; Lee HH; Wang W; Yao Y; Nie L; Flowers CR; Wang M
J Clin Invest; 2023 Feb; 133(3):. PubMed ID: 36719376
[TBL] [Abstract][Full Text] [Related]
8. Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors.
Burkart M; Karmali R
J Pers Med; 2022 Mar; 12(3):. PubMed ID: 35330376
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib enhances the anti-cancer effect of the novel Bruton's tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK.
Wang X; Fei Y; Liu X; Zhang T; Li W; Jia X; Liu X; Qiu L; Qian Z; Zhou S; Ren X; Zhai Q; Meng B; Li L; Zhang H
Aging (Albany NY); 2021 Sep; 13(17):21102-21121. PubMed ID: 34508613
[TBL] [Abstract][Full Text] [Related]
10. Cooperative miRNA-dependent PTEN regulation drives resistance to BTK inhibition in B-cell lymphoid malignancies.
Kapoor I; Bodo J; Hill BT; Almasan A
Cell Death Dis; 2021 Nov; 12(11):1061. PubMed ID: 34750354
[TBL] [Abstract][Full Text] [Related]
11. Beyond Bruton's tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody-drug conjugates, CAR T-cells, and novel agents.
Jain N; Mamgain M; Chowdhury SM; Jindal U; Sharma I; Sehgal L; Epperla N
J Hematol Oncol; 2023 Aug; 16(1):99. PubMed ID: 37626420
[TBL] [Abstract][Full Text] [Related]
12. Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma.
Thieme E; Liu T; Bruss N; Roleder C; Lam V; Wang X; Nechiporuk T; Shouse G; Danilova OV; Bottomly D; McWeeney SK; Tyner JW; Kurtz SE; Danilov AV
Cell Death Dis; 2022 Mar; 13(3):246. PubMed ID: 35296646
[TBL] [Abstract][Full Text] [Related]
13. Identification of six hub genes in mantle cell lymphoma patients with BTKi resistance.
Liu S; Yang P; Wang L; Li C; Zhang W; Wang J; Jing H
Ann Transl Med; 2022 Oct; 10(20):1105. PubMed ID: 36388812
[TBL] [Abstract][Full Text] [Related]
14. The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.
Li J; Wang X; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Pan Z; Ding N; Song Y; Zhu J
Int J Cancer; 2018 Jan; 142(1):202-213. PubMed ID: 28905990
[TBL] [Abstract][Full Text] [Related]
15. HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib.
Yang G; Buhrlage SJ; Tan L; Liu X; Chen J; Xu L; Tsakmaklis N; Chen JG; Patterson CJ; Brown JR; Castillo JJ; Zhang W; Zhang X; Liu S; Cohen P; Hunter ZR; Gray N; Treon SP
Blood; 2016 Jun; 127(25):3237-52. PubMed ID: 27143257
[TBL] [Abstract][Full Text] [Related]
16. Pirtobrutinib: A novel non-covalent BTK inhibitor for the treatment of adults with relapsed/refractory mantle cell lymphoma.
Davis DD; Ohana Z; Pham HM
J Oncol Pharm Pract; 2024 Jan; 30(1):182-188. PubMed ID: 38043933
[TBL] [Abstract][Full Text] [Related]
17. Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma.
Li CJ; Jiang C; Liu Y; Bell T; Ma W; Ye Y; Huang S; Guo H; Zhang H; Wang L; Wang J; Nomie K; Zhang L; Wang M
Mol Cancer Ther; 2019 Feb; 18(2):267-277. PubMed ID: 30413649
[TBL] [Abstract][Full Text] [Related]
18. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.
Chiron D; Di Liberto M; Martin P; Huang X; Sharman J; Blecua P; Mathew S; Vijay P; Eng K; Ali S; Johnson A; Chang B; Ely S; Elemento O; Mason CE; Leonard JP; Chen-Kiang S
Cancer Discov; 2014 Sep; 4(9):1022-35. PubMed ID: 25082755
[TBL] [Abstract][Full Text] [Related]
19. PIK-75 overcomes venetoclax resistance
Huang S; Liu Y; Chen Z; Wang M; Jiang VC
Am J Cancer Res; 2022; 12(3):1102-1115. PubMed ID: 35411248
[TBL] [Abstract][Full Text] [Related]
20. p110α Inhibition Overcomes Stromal Cell-Mediated Ibrutinib Resistance in Mantle Cell Lymphoma.
Guan J; Huang D; Yakimchuk K; Okret S
Mol Cancer Ther; 2018 May; 17(5):1090-1100. PubMed ID: 29483220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
